Clinical trial
A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir
NCT00940485 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2009
- Completion date
- December 31, 2011
- Enrollment
- 200 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.